Critical review of growth factors as clinical tools in primary and metastatic breast cancer.
Klijn
J G
JG
Department of Medical Oncology, Rotterdam Cancer Institute (DDHK), The Netherlands.
Berns
P M
PM
van Putten
W L
WL
Bontenbal
M
M
Alexieva-Figusch
J
J
Foekens
J A
JA
D001943:Breast Neoplasms / Q000737:chemistry / Q000401:mortality* / Q000628:therapy; D066246:ErbB Receptors / Q000032:analysis; D005260:Female; D006133:Growth Substances / Q000032:analysis*; D006801:Humans; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000032:analysis; D018719:Erb-b2 Receptor Tyrosine Kinases; D017526:Receptor, IGF Type 1 / Q000032:analysis; D011956:Receptors, Cell Surface / Q000032:analysis*; D017481:Receptors, Somatostatin / Q000032:analysis; D015996:Survival Rate; D016212:Transforming Growth Factor beta / Q000235:genetics
D066246:ErbB Receptors; D006133:Growth Substances; D011518:Proto-Oncogene Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D017526:Receptor, IGF Type 1; D011956:Receptors, Cell Surface; D017481:Receptors, Somatostatin; D016212:Transforming Growth Factor beta